INVESTIGATOR PROTOCOL AGREEMENT PAGEInvestigator Protocol Agreement • May 22nd, 2019
This study will not commence without the prior written approval of a properly constituted Institutional Review Board (IRB). No changes will be made to the study protocol without the prior written approval of the sponsor and the IRB, except where necessary to eliminate an immediate hazard to the patient.
INVESTIGATOR PROTOCOL AGREEMENT PAGEInvestigator Protocol Agreement • November 10th, 2024
INVESTIGATOR PROTOCOL AGREEMENTInvestigator Protocol Agreement • May 24th, 2022
Title: A SU2C Catalyst® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab (Keytruda®) with vitamin D receptor agonist Paricalcitol (Zemplar®) in Patients with Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response (with no further improvement in their tumor)
SIGNATURE PAGEInvestigator Protocol Agreement • July 29th, 2021
INVESTIGATOR PROTOCOL AGREEMENT PAGEInvestigator Protocol Agreement • September 20th, 2022
INVESTIGATOR PROTOCOL AGREEMENT PAGEInvestigator Protocol Agreement • April 12th, 2015
This study will not commence without the prior written approval of a properly constituted Institutional Review Board (IRB). No changes will be made to the study protocol without the prior written approval of the sponsor and the IRB, except where necessary to eliminate an immediate hazard to the patient.
INVESTIGTOR PROTOCOL AGREEMENT PAGEInvestigator Protocol Agreement • February 19th, 2018
• To assume responsibility for the proper conduct of the study at this site and supervise all testing of the device involving human subjects
